4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Background There are no published clinical consensus guidelines or systematic evaluation
supporting the use of corticosteroids for the treatment of cardiac sarcoidosis. The purpose of …

Sarcoidosis is a systemic granulomatous disease of unknown cause. Sarcoidosis involving
the heart, ie, cardiac sarcoidosis, affects the prognosis of patients significantly as it may lead …

Developing consensus recommendations for rare diseases requires adapting the
methodology for preparing traditional guidelines for clinical practice. The most obvious …

Background—Giant-cell myocarditis often escapes diagnosis until autopsy or transplantation
and has defied proper treatment trials for its rarity and deadly behavior. Current therapy rests …

Background—Cardiac sarcoidosis is associated with an increased risk of heart failure and
sudden death, but its risk in patients with preserved left ventricular ejection fraction is …

Background—Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) may present as
high-degree atrioventricular block (AVB), but their proportion of the causal spectrum of AVB …

The prevalence of sarcoidosis-related cardiomyopathy is increasing. Sarcoidosis impacts
cardiac function through granulomatous infiltration of the heart, resulting in conduction …

Background Corticosteroid therapy for the treatment of clinically manifest cardiac sarcoidosis
is generally recommended. Our group previously systematically reviewed the data in 2013; …

Cardiac Sarcoidosis Presenting as Atrioventricular Block Introduction Atrioventricular block
(AVB) can be caused by several conditions, including cardiac sarcoidosis (CS). The …